Trinity Biotech Plc Stock Price To Earnings To Growth
| TRIB Stock | USD 1.82 0.01 0.55% |
Trinity Biotech plc fundamentals help investors to digest information that contributes to Trinity Biotech's financial success or failures. It also enables traders to predict the movement of Trinity Stock. The fundamental analysis module provides a way to measure Trinity Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trinity Biotech stock.
Trinity | Price To Earnings To Growth |
Trinity Biotech plc Company Price To Earnings To Growth Analysis
Trinity Biotech's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Trinity Biotech Price To Earnings To Growth | 1.30 X |
Most of Trinity Biotech's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trinity Biotech plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trinity Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Trinity Biotech is extremely important. It helps to project a fair market value of Trinity Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Trinity Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trinity Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trinity Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Trinity Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Trinity Biotech plc has a Price To Earnings To Growth of 1.3 times. This is 83.1% higher than that of the Health Care Equipment & Supplies sector and 156.28% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 73.42% higher than that of the company.
Trinity Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trinity Biotech's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trinity Biotech could also be used in its relative valuation, which is a method of valuing Trinity Biotech by comparing valuation metrics of similar companies.Trinity Biotech is currently under evaluation in price to earnings to growth category among related companies.
Trinity Fundamentals
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 331.73 M | ||||
| Shares Outstanding | 7.64 M | ||||
| Shares Owned By Insiders | 29.31 % | ||||
| Shares Owned By Institutions | 39.28 % | ||||
| Number Of Shares Shorted | 1.86 K | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.25 X | ||||
| Revenue | 56.83 M | ||||
| Gross Profit | 38.08 M | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (36.87 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 54.86 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (3.12) X | ||||
| Cash Flow From Operations | (19.18 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (4.96) X | ||||
| Price To Earnings To Growth | 1.30 X | ||||
| Target Price | 3.0 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 13.98 M | ||||
| Total Asset | 59.44 M | ||||
| Retained Earnings | (48.64 M) | ||||
| Working Capital | 29.33 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
| Net Asset | 59.44 M |
About Trinity Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Trinity Biotech plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trinity Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trinity Biotech plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out Trinity Biotech Piotroski F Score and Trinity Biotech Altman Z Score analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Trinity Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (4.96) | Revenue Per Share 7.424 | Quarterly Revenue Growth (0.26) | Return On Assets (0.13) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.